Author Archives: Chandra Ganegoda

BriaCell Presents Outstanding Phase 2 Survival & Promising Phase 3 Clinical Data at SABCS® 2025

BriaCell presents positive clinical data in three posters at the San Antonio Breast Cancer Symposium ...

BriaCell’s Phase 3 Patient Enrollment on Track for 1H2026 Topline Data Readout

Over 230 patients screened and over 160 patients enrolled in BriaCell’s pivotal Phase 3 study ...

BriaCell to Present Phase 2 Survival & Phase 3 Clinical Data at SABCS® 2025

Three poster presentations at the San Antonio Breast Cancer Symposium (SABCS), now available and to ...

BriaCell to Highlight Positive Phase 2 & Phase 3 Clinical Data at SABCS® 2025

Three poster presentations at the San Antonio Breast Cancer Symposium (December 10, 2025) will highlight ...

BriaCell and Receptor.AI to Collaborate on AI Driven Small Molecule Cancer Therapeutics

Collaboration uses Receptor AI’s platform to design highly selective anti-cancer kinase inhibitor products for BriaPro, ...

BriaCell Selected to Present Phase 2 & 3 Clinical Data at SABCS® 2025

Three BriaCell poster presentations include updated key biomarker data from BriaCell’s pivotal Phase 3 study ...

BriaCell Presents Robust Anti-Cancer Activity of Bria-OTS+(TM) at SITC 2025

Next generation Bria-OTS+ platform demonstrates rapid, potent and durable anti-cancer activity by activating both innate ...

BriaCell to Present Robust Anti-Cancer Activity of Bria-OTS+(TM) in Breast and Prostate Cancer Models

SITC poster to be presented on Friday, November 7, 2025, emphasizes robust anti-cancer activity of ...

BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer

Independent DSMB has identified no safety concerns, and recommends continuation of BriaCell’s pivotal Phase 3 ...

BriaCell Adds Key Clinical Sites in Phase 3 Metastatic Breast Cancer Study

79 clinical sites across 23 US states are currently enrolling patients in BriaCell’s pivotal Phase ...